Podcasts about pre-exposure prophylaxis

In this rapid webinar, Meredith E. Clement, MD, and Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, provide an overview of important topics and studies presented at HIVR4P 2024, including:Expanding PrEP options based on results from PURPOSE 2, IMPOWER-22, IMPOWER-24, IPM 054, MTN-025/HOPE OLE, CATALYST, and the HPTN 084 substudyImplementing injectable PrEP based on results from PEPFAR, the USAID DISCOVER-Health LA CAB Demonstration Project in Zambia, and the LA CAB PrEP Rapid Start Model in Public Health ClinicsImproving PrEP uptake based on results from SPrEP and HPTN 091  Presenters:Meredith E. Clement, MDAssociate ProfessorInfectious DiseasesLouisiana State University Health Sciences CenterNew Orleans, LouisianaLinda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhDDirector and Professor, The Desmond Tutu HIV Centre, UCTCEO, The Desmond Tutu Health FoundationCape Town, South AfricaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Link to full program: https://bit.ly/3NJIDSA

In this rapid webinar, Meredith E. Clement, MD, and Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, provide an overview of important topics and studies presented at HIVR4P 2024, including:Expanding PrEP options based on results from PURPOSE 2, IMPOWER-22, IMPOWER-24, IPM 054, MTN-025/HOPE OLE, CATALYST, and the HPTN 084 substudyImplementing injectable PrEP based on results from PEPFAR, the USAID DISCOVER-Health LA CAB Demonstration Project in Zambia, and the LA CAB PrEP Rapid Start Model in Public Health ClinicsImproving PrEP uptake based on results from SPrEP and HPTN 091 Presenters:Meredith E. Clement, MDAssociate ProfessorInfectious DiseasesLouisiana State University Health Sciences CenterNew Orleans, LouisianaLinda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhDDirector and Professor, The Desmond Tutu HIV Centre, UCTCEO, The Desmond Tutu Health FoundationCape Town, South AfricaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Link to full program: https://bit.ly/3NJIDSA

Can a twice-yearly shot provide 100% protection against HIV? Find out about this and more in today's PeerDirect Medical News Podcast.

In this episode, Roger Bedimo, MD, MS, FACP, examines provider-based and structural PrEP barriers and discusses practical methods for healthcare professionals to overcome these challenges. Topics covered include:Potential provider barriers to prescribing PrEPStrategies to facilitate conversations about PrEPAddressing the gap in PrEP provider trainingStructural barriers for PrEP coverage, such as lack of insurance and complexity of billingInformed consent for minorsCDC guidelines on HIV testing and renal or lipid monitoring while on PrEPThe role of PrEP champions or PrEP navigators, such as in the SNAPS PrEP Navigation ProgramSolutions to common problems with PrEP persistence, such as use of telehealth and same-day PrEP initiationExpanding PrEP optionsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Roger Bedimo, MD, MS, FACP, discusses strategies to overcome health disparities to improve PrEP uptake, including:Targeting key populations that would benefit from PrEP but have low rates of uptake, such as transgender women and people who inject drugsAddressing intersectionalityOvercoming implicit biasAddressing PrEP inequity by geographic regionExpanding PrEP uptake by expanding HCPs who prescribe itImproving PrEP education for both patients and HCPsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Roger Bedimo, MD, MS, FACP, examines patient and regimen-based PrEP barriers and discusses practical interventions to support PrEP adherence in key populations. Topics covered include:Individual and community perspectives on PrEP barriersKey barriers by principal populationsStrategies to support PrEP deliveryPrEP options for key populationsPrEP efficacy based on adherence in cisgender men and womenComparing FTC/TDF vs FTC/TAF or CAB for PrEPPrEP in pregnancy and breastfeedingDrug–drug interactions with gender-affirming hormone therapyPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the updated CDC guidance on how to monitor for HIV in people receiving PrEP, including:Rationale for why HIV monitoring differs for people receiving LA vs daily PrEPDescription of LEVI syndromeHow to transition a person from LA PrEP to HIV ART if they test positive for HIV Presenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program: https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  

In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, and Nimish Patel, PharmD, PhD, AAHIVP, cover the most impactful clinical studies presented at CROI 2024, including:New data on long-acting ART, including:The CARES study of LA CAB + RPV in a sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco's Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on HIV and STI prevention, including:The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoBIC/FTC/TAF for PEPOffering PrEP following PEPPresenters:Samantha Strong, PharmD, BCACP, AAHIVP, CDCESClinical Director of PharmacyNevada Health CentersLas Vegas, NevadaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here: https://bit.ly/49x0W6D

In this episode, David Saunders discusses the value of nonstigmatizing discussions between people using HIV pre-exposure prophylaxis (PrEP) and healthcare professionals, including: Encouraging accountability to individualize adherence strategies and improve persistence to PrEPReducing stigma, discrimination, and prejudice in healthcare settings to foster PrEP persistence Faculty: David SaundersPrEP User and AdvocateLink to full program:https://bit.ly/3ZlICsLTo automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast.

In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including: The importance of having PrEP navigators to help with logistics and be a point of contact for patients Where to find education and resources to familiarize yourself with PrEP and its prescribingSafety considerations and adverse events associated with PrEP optionsPrEP coverage and costHow to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEPFacultyTavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaAnne Teitelman, PhD, FNP-BC, FANNP, FAANAssociate Professor Emeritus of Nursing and Global Women's HealthDepartment of Family and Community HealthSchool of NursingUniversity of PennsylvaniaProfessorThomas Jefferson UniversityCollege of NursingPhiladelphia, PennsylvaniaLink to full program: https://bit.ly/3PZGYdR

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:Available training resources on how to offer PrEP in primary careAffordable, accessible PrEP options, including patient assistance programsUsing electronic health records to identify candidates for PrEPOpportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concernsHow to offer 3-site STI testing at your facilityWrapping PrEP into primary careIncorporating navigators or care coordinators to reduce logistical barriers and reach underserved populationsRapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visitsHealthcare professionals' personal biases as a potential barrier to PrEPUsing ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billingFaculty:Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaJona Tanguay, MMSc, PA-C, AAHIVSMedical Program Lead - Substance Use Disorders at Whitman-Walker HealthAssociate Medical Director - Transgender Health at Amida CarePresident-Elect at GLMA: Health Professionals Advancing LGBTQ+ EqualityClinical Instructor at Yale School of MedicineFounder at ChemsexHarmReduction.orgWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, Errol L. Fields, MD, PhD, MPH, and Armonté Butler, MPH, a pre-exposure prophylaxis (PrEP) advocate, discuss strategies for overcoming barriers to uptake of PrEP for HIV in adolescents and young adults, based on the unique needs of this patient population. Topics covered include:Methods for building trust between patients and providersWays to practice shared decision-making and how this process hinges on respecting patients' autonomy and personhoodHow to empower young people to ask for the assistance they needHow to navigate consent and confidentiality issuesInformation about payment optionsStrategies to improve adherence for youthThe best ways to provide support and flexibility throughout this process to promote persistence on PrEP Faculty:Errol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandArmonté Butler, MPHAssociate Director, LGBTQ Health & RightsAdvocates for YouthWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, Martin Rios discusses how pre-exposure prophylaxis (PrEP) persistence depends on healthcare professional knowledge, including:Their own experiences with the various PrEP providers they have seenThe relief that has come with seeing PrEP providers who are supportive and knowledgeable about the different PrEP optionsThe challenges that have come with seeing PrEP providers who are unwilling to prescribe PrEP altogether or who will prescribe PrEP when asked but are not knowledgeable about the optionsFaculty: Martin RiosPrEP User and AdvocatePhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3ZlICsL

Brazil's Proactive Measures Against HIVBrazil has been at the forefront of combating HIV, implementing proactive measures that have made a significant difference. The country began providing no-cost access to CD4 and viral load testing and antiretroviral drugs as early as 1996. This early intervention and consistent approach led to a remarkable outcome: the number of HIV cases in Brazil was significantly lower than initially predicted. An article from the New England Journal of Medicine stated that initial estimates predicted Brazil would have 1.2 million people infected with HIV by the year 2000, but with the strategies the country put in place, their actual numbers were about half of what was predicted. By offering free access to treatments and diagnostic tests, Brazil showcased the importance of early and sustained intervention in managing and reducing the spread of HIV. The Rising Challenge of HIV Drug ResistanceOne of the most pressing challenges in the fight against HIV is the development of drug resistance. Dr. Ricardo Diaz emphasizes that as the HIV virus replicates, it can produce strains resistant to treatment. This resistance threatens the efficacy of antiretroviral drugs, making it crucial to monitor and manage. The World Health Organization reports an increasing rate of HIV drug resistance, underscoring the need for continuous research, monitoring, and adaptation of treatment strategies. Pre-exposure Prophylaxis (PrEP) Drugs Exist, but are not 100% EffectivePrEP, or pre-exposure prophylaxis, is also an antiretroviral drug given to uninfected individuals who are at risk of infection to reduce their chances of acquiring HIV. PrEP is highly effective at preventing HIV when taken as indicated, but much less effective when it isn't taken consistently. Additionally, it's possible to be exposed to HIV strains that are drug resistant while on PrEP, so monitoring resistance in people on PrEP is another important step in prevention. The Gap in HIV Drug Resistance TestingDespite the advancements in treatment, there's a noticeable disparity in HIV drug resistance testing, especially in Brazil. Dr. Diaz highlights that while a centralized lab in Brazil performs genotype testing, the number of tests conducted falls short of the actual need. With 10% of patients on treatment showing a viral load above the desired limit, the demand for resistance testing is evident. Bridging this gap and increasing surveillance efforts is essential to tailor treatments effectively and combat the spread of drug-resistant HIV strains.

In this podcast, experts Sarah M. Wood, MD, MS, and Errol L. Fields, MD, PhD, MPH, discuss some of the challenges and concerns clinicians face when prescribing PrEP to adolescents. The faculty addresses the potential for adverse effects from PrEP, including the potential for renal impairment, decreased bone density, and whether PrEP can interfere with hormone therapy for gender-affirming care. They review the data behind these concerns and emphasize that the vast majority of adverse effects caused by PrEP are mild and reversible.The experts also examine common barriers that adolescents face when attempting to initiate and adhere to PrEP, such as insurance coverage and confidentiality. Dr Fields and Dr Woods discuss strategies for overcoming these barriers and retaining adolescents on PrEP, including how to navigate tricky conversations with both patients and parents or within communities that may stigmatize PrEP and HIV.Sarah M. Woods, MD, MSAssistant Professor of PediatricsDivision of Adolescent MedicineUniversity of Pennsylvania Perelman School of MedicineChildren's Hospital of PhiladelphiaPhiladelphia, PennsylvaniaErrol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandContent based on an online CME program supported by independent educational grants from Gilead Sciences Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, Tony Brown, MPH, discusses the importance of effective patient‒provider communication in supporting PrEP persistence including: His own experience with PrEP and reasons for fluctuations in adherence over the years The importance of open, honest, and judgement-free conversations about sexual health Engaging patients in conversations about PrEP effectiveness, adverse effects, and changing life circumstances Working together to find the most effective PrEP option for each individual patient that will help them to persist on PrEP long term Faculty: Tony Brown, MPH PrEP User and Advocate Doctoral Candidate Health Services Policy and Management University of South Carolina Columbia, South Carolina Link to full program: https://bit.ly/3ZlICsL

In this episode, Jill Blumenthal, MD, MAS, and Kenric B. Ware, PharmD, MBA, AAHIVP, answer questions about HIV PrEP including:Considerations for selecting between oral and injectable PrEP in college studentsStrategies to promote PrEP persistence in adolescents Best approaches to address readiness to start PrEP in adolescents (eg, creating nonjudgmental environments, addressing misconceptions)Considerations for local consent lawsAvailable data on PrEP young adolescents (eg, age and weight limits)Initiatives in place to address racial and ethnic disparities associated with PrEP uptake and persistence The role of on-demand PrEP in transgender individuals receiving gender-affirming hormone therapy Offering patient-centered care Educating healthcare professionals on how to prescribe PrEPFaculty: Jill Blumenthal, MD, MAS Associate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaKenric B. Ware, PharmD, MBA, AAHIVP Clinical Associate ProfessorDepartment of Pharmacy PracticeMercer University College of PharmacyAtlanta, GeorgiaLink to full program: https://bit.ly/3Fqdgs9

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:The importance of taking a sexual history and getting to know your patientRecommendations for who should be considered for PrEPPracticalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribingSummary of PrEP eligibility by regimenReview of the clinical trial and real-world data for each PrEP modalityThe likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEPTime to effective concentrations of PrEP after initiationWhether there are data for on-demand dosing of FTC/TAFRecommendations for FTC/TDF on demand for heterosexual cisgender menIndividualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacyRecommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potentialSTI and point-of-care testing for people receiving PrEPThe possibility of implantable PrEP in the futurePresenters:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV Centre University of Cape TownCape Town, South AfricaMeredith Clement, MD Assistant ProfessorSection of Infectious DiseasesLouisiana State University Health Sciences CenterUniversity Medical CenterNew Orleans, Louisiana Link to full program:https://bit.ly/3HPu4Lk

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:How long someone can receive PrEP and the monitoring that is needed over timeRecommendations for monitoring bone health while receiving oral PrEPTreatment as prevention and PrEP efficacy data and options for people who inject drugsThe role of circumcision in HIV preventionThe use of PrEP in pregnancyConcern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP optionsThe possibility of using FTC/TAF on demandInequities in adherence and persistenceCost considerations with different PrEP modalitiesRecommendations for hospitalized patients receiving PrEPPrEP considerations for patients with renal dysfunction and higher BMIsPrEP efficacy based on site of exposurePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaJason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, MarylandLink to full program:https://bit.ly/3Fqdgs9

In this episode of Viva La Vulva, we explore the intersection of HIV, Pre-exposure prophylaxis (PrEP), and Black women's health. Our guests include Nikole Trainor (Public Health Practitioner), Lashae Alexander (sex educator), and Coloni Brown (a Black Woman taking PrEP). We dive into the current state of HIV among Black women and how PrEP can potentially prevent new cases of HIV. Nikole Trainor gives us insight into the initiatives and resources available for Black women to access PrEP and other sexual health services. Lashae Alexander guides us through how to have safer sex discussions and practices. And Coloni Brown shares her personal journey of why she started PrEP in the first place and how she's doing on the medicine. Finally, we discuss the stigma and misconceptions surrounding HIV and PrEP and how it affects Black women. Join us in this important conversation about sexual health, empowerment, and breaking down barriers to access.   Resources: To order Free in-home HIV + other STI testing kits go to: www.havegoodsex.org Lashae Alexander (sex educator) www.shaedaily.com @shaeislove Nikole Trainor (Public Health Practitioner) @goodsexsf Coloni Brown  @coloni026 Dr. Cara Quant (host) @vivalavulvala and @drcaraquant

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations Key remaining questions related to PrEP options for cisgender women and people who inject drugsConcerns about resistance at seroconversion in patients with suboptimal PrEP complianceImplementation of molecular screening for patients receiving PrEPExpectations for weight gain and patient counseling pointsPresenters:Carolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficerAmerican Academy of HIV MedicineChief Clinical OfficerNational Clinician Consultation CenterSamantha Strong, PharmD, BCACP, AAHIVP, CDCES Clinical Director of PharmacyNevada Health CentersLas Vegas, NevadaLink to full program: https://bit.ly/3Fqdgs9

In this episode, Kenric Ware, PharmD, AAHIVP, discusses the role of college campuses in HIV pre-exposure prophylaxis (PrEP) uptake for adolescents, including the following.PrEP awareness and educationVenues for ongoing PrEP conversations, including in-person dormitory discussions, virtual webinars, and social media conversationsCampus health clinics that are safe and trusting and minimize stigmaIndividualized approaches, including:Engaging local students in discussions of regional barriers and facilitators to PrEP uptake on their campusRecruiting PrEP ambassadors with social capital on campus, such as student athletes or sorority or fraternity leadersIdentifying faculty and administrator PrEP champions to amplify and provide continuity and support to student PrEP messagingKenric Ware, PharmD, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice South UniversitySavannah, GeorgiaChairperson, PharmacistBoard of DirectorsJoseph H. Neal Health CollaborativeColumbia, South Carolina See the full program at: http://bit.ly/3WhbBvZ

In this episode, Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, discusses optimizing HIV pre-exposure prophylaxis (PrEP) selection and persistence for men who have sex with men (MSM), including:Disparities in PrEP uptake for MSMWhat healthcare professionals can do to address disparities in PrEP uptakeProviding PrEP within a program that includes sexual health and primary care services, in addition to prescribing PrEPPrEP medication options for MSMHelping patients access PrEP medicationsBarriers to PrEP persistenceStrategies for aiding in PrEP persistence, including:          - Increasing access to healthcare professionals through text messaging and telemedicine         - Ensuring a welcome and sex-positive environment         - Partnering with pharmacists and community health workers for follow-up Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, Maryland See the full program at: https://bit.ly/3WhbBvZ

In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:Providing gender-affirming careIntegrating PrEP and gender careTaking a sexual history and addressing sexual healthPrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CABThe importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options Jill Blumenthal, MD, MAS (she/hers)Associate Professor of MedicineInfectious Diseases and Global Public HealthUniversity of California, San DiegoSan Diego, California See the full program at: https://bit.ly/3WhbBvZ

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses improving HIV pre-exposure prophylaxis accessibility and availability for PWID, including by:Integrating PrEP with services that PWID are already aware of and/or connected to (eg, harm reduction/syringe services and substance use disorder treatment programs, peer-based training/education initiatives, healthcare for the homeless programs, and emergency departments) Staffing PrEP programs with people who are trusted by PWID and delivering PrEP in settings where patients feel respected, comfortable, and safe Tailoring prescribing practices and interventions (eg, same-day medication initiation, on-site pharmacies and/or medication storage, and intensive outreach and navigation) to support the care needs of PWIDCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficeAmerican Academy of HIV MedicineSee the full program at: https://bit.ly/3WhbBvZ

In this episode, Winnie Sseruma and Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discuss some of the barriers to genuinely patient-centered HIV care in Africa and offer calls to action for healthcare professionals for responding to patient preferences.They discuss the efforts to improve patient-centered HIV care in the foundations and organizations for which they work. They also address issues related to stigma around HIV and complacency and lack of visibility for HIV.You will then hear them talk through differentiated service delivery in South Africa and Mozambique as models for other parts of Africa. They focus on HIV prevention and some of the difficulties of reaching certain populations to better communicate effective prevention practices.They end with a discussion about the importance of documenting the experiences and stories of people living with HIV.Winnie SserumaInternational Development Consultant London, United KingdomLinda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV CentrePast PresidentInternational AIDS SocietyFaculty of Health SciencesUniversity of Cape TownCape Town, South AfricaLink to full program:https://bit.ly/3Fxsfkz

In this episode, Iskandar Azwa, MBChB, and patient advocate Andrew Tan Tze Tho discuss barriers to genuinely patient-centered HIV care in Malaysia and the surrounding region and offer calls to action for healthcare professionals for responding to patient preferences.They discuss health literacy programs and other forms of effective health communication, especially with respect to disparate communities. They also address the prevalence of late presentation in Malaysia and the importance of getting people tested and into care earlier.They then discuss the urgency of rapid initiation of antiretroviral therapy, discrepancies in access to health services, and stigma and discrimination.Finally, they discuss the issues preventing newer antiretrovirals from being more readily available to people in the region; the importance of maintaining and refining patient-focused, differentiated care in the face of such disparities; and the role of advocates and healthcare professionals in helping to drive those improvements. Iskandar Azwa, MBChBAssociate ProfessorInfectious Diseases, Faculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaAndrew Tan Tze ThoPresidentKuala Lumpur AIDS Support Services Society (KLASS)Kuala Lumpur, MalaysiaLink to full program:https://bit.ly/3Fxsfkz

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses PrEP uptake for cisgender women. His discussion includes: Prevalence of PrEP use in cisgender women in the United StatesBarriers to PrEP uptake in cisgender womenImplementation of PrEP within family planning clinics in AtlantaPrEP in pregnancy and breastfeedingPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program: http://bit.ly/3UFUl2bFollow along with the slides at:http://bit.ly/3TDOPM8

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake for people who inject drugs. His discussion includes: PrEP uptake and recommendations for people who inject drugsProject SHE: integrating PrEP with community-based syringe services for women who inject drugsPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, focuses on transgender women. His discussion includes: Barriers to PrEP uptake in transgender womenHigh PrEP adherence among transgender women and transfeminine individuals in a real-world healthcare setting in New York CityPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses solutions to expanding PrEP uptake. His discussion includes: Potential healthcare professional barriers to prescribing PrEPAddressing the gap in PrEP training for healthcare professionalsExpanding PrEP options to facilitate adherence and persistence: today and in the near futureImmediate PrEP initiation at New York City sexual health clinicsProviding PrEP by telehealthTake-home points on expanding PrEP uptakePresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake in the context of racial inequities, specifically for Black and Latinx communities. His discussion includes: Inequities in PrEP uptake in Black and Hispanic and Latinx people compared with White peopleStructural barriers to PrEP adoptionKaiser Permanente study (2012-2019): PrEP continuum of care and new HIV infectionsEle[MEN]t study: PrEP persistence and discontinuation in young Black men who have sex with menCreating change: education of patients and healthcare professionals to address inequities in PrEP uptakePresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at: https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake for adolescents. His discussion includes: How PrEP is underused in adolescents and young adultsHealthcare professional barriers to provision of PrEP for adolescentsA systematic review and meta-analysis of adherence to PrEP in adolescents and young adultsBarriers to adherence in adolescents and young adultsInterventions to support PrEP adherence in adolescentsPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program: https://bit.ly/3VIsDTgFollow along with the slides at:https://bit.ly/3EcaYg0 

In this episode, Marc Thompson and Tristan J. Barber, MA, MD, FRCP, discuss some of the barriers to genuinely patient-centered HIV care in the United Kingdom and offer calls to action for healthcare professionals for responding to patient preferences. They discuss barriers to HIV testing and effectively communicating the benefits of testing to disparate communities. They also talk through the difficulties in maintaining patient engagement in HIV care and the value of using peer support workers in HIV clinics. You will then hear Marc and Dr Barber talk through treatment and prevention practices. They focus on the importance of messaging around U=U: that treatment can make a patient's HIV undetectable, and therefore their HIV is untransmissible. They end with a discussion about changing treatment paradigms and how to keep patients informed and empowered—not overwhelmed—by those changes to help ensure lasting health outcomes.Marc ThompsonDirector, The Love TankCo-founder, PrepsterLondon, United KingdomTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom Link to full program:https://www.clinicaloptions.com/hiv/programs/2022/what-pts-want-hiv

In this episode, Deondre Moore and Samantha V. Hill, MD, MPH, discuss some of the barriers to genuinely patient-centered HIV care in the United States and offer calls to action for healthcare professionals for responding to patient preferences. They talk through some of the barriers that patients face, from struggling with unfamiliar medical terminology, to healthcare professional biases, to more structural problems like housing and food scarcity. They also discuss strategies that healthcare professionals can incorporate to provide more comprehensive, inclusive, collaborative HIV care. Samantha V. Hill, MD, MPHAssistant ProfessorDivision of Adolescent MedicineDepartment of PediatricsThe University of Alabama at BirminghamBirmingham, AlabamaDeondre MooreU.S. Partnerships and Community Engagement ManagerPrevention Access CampaignHouston, TexasLink to full program:https://bit.ly/3fsWuij

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:Prevention strategiesOral therapiesLA therapiesCureCOVID-19 in PWHFacultyChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomFollow along with the slides atbit.ly/3SLuhBq

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD Data from the ANRS IPERGAY study on the use of FTC/TDF on demand Data from the DISCOVER trial on the use of FTC/TAF for PrEP Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men Clinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MDAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaKarine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, FranceContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uqPje3Link to full program:https://bit.ly/3q2DlGd

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including: Discussion of the PrEP gap and racial and gender disparities in PrEP accessCDC, EACS, and WHO guidance on PrEP eligibilityPrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravirData from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEPPharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender womenData and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPEData from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender womenRecommendations for the use of PrEP during pregnancy and breastfeedingClinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, Alabama Karine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, France Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at: https://bit.ly/36s2ovBLink to full program:https://bit.ly/3q2DlGd

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).- Listen as he gives his perspectives on:- The FDA approval of long-acting cabotegravir for PrEP- Healthcare professionals' clinical concerns with long-acting injectable antiretroviral therapy- Considerations for long-acting cabotegravir as PrEPDosing and administrationManaging missed dosesDiscontinuationDelays in HIV diagnoses found in the HPTN 083 study in men- CDC recommendations for HIV screening while receiving PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania  Follow along with the slides at: https://bit.ly/3wugMOCSee the entire program at: https://bit.ly/3q2DlGd

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).Listen as he gives his perspectives on the:PrEP pipeline and the importance of having options for patients with differing preferencesFDA approval of long-acting cabotegravir for PrEPHPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarateSafety data on long-acting cabotegravir for PrEPCDC recommendations on the management of injection-site reactions with cabotegravir for PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at:https://bit.ly/3tbvEPKSee the entire program at: https://bit.ly/3q2DlGd

In this episode, Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV, and Solange L. Baptiste, ScM, discuss the burden of HIV among BIPOC and migrant communities and key strategies to reduce racial disparities in HIV care globally:Disproportionate impact of HIV among BIPOC communities and migrant populations globallyBarriers to HIV testing, prevention, and treatment services among BIPOC communities and migrant populationsStrategies to overcome health system–based and provider-based barriers to engagement with HIV careRageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIVHonorary Senior Lecturer in HIV MedicineBlizard Institute, Faculty of Medicine and DentistryQueen Mary University of LondonConsultant Physician in HIV MedicineDepartment of Infection and ImmunityBarts Health NHS TrustLondon, United KingdomSolange L. Baptiste, ScMExecutive DirectorInternational Treatment Preparedness CoalitionBryanston, South AfricaContent based on a CME program supported by educational grants from AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP  To follow along, download the slides at:https://bit.ly/3ngDrsvLink to full program:https://bit.ly/3gh6WXj

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:Rationale for use of mAbPotential for resistance to mAbSingle vs combination therapy with mAbChallenges in implementation of mAb as treatment or preventionBamlanivimabSotrovimabCasirivimab plus imdevimabLink to full program, including downloadable slidesets:  https://bit.ly/3zVTwYWPresenters: Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesFaculty Medicine Dentistry and Health SciencesUniversity of Melbourne and Royal Melbourne HospitalConsultant Infectious Diseases PhysicianDepartment of Infectious DiseasesRoyal Melbourne Hospital and Alfred HospitalMelbourne, AustraliaArthur Kim, MDAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Viral Hepatitis ClinicDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsSharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  This episode includes discussion of:An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWHCALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWHA Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patientsA Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEPZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TBPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases  Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.  This episode includes discussion of:A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimensA Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimenPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases  Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/2WZu7zmContent based on an online CME program supported by an educational grant from ViiV Healthcare.

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCThe 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCAn extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patientsThe CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic settingThe HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender womenThe CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectivelyIn addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.Presenters:Jennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaJason Schafer, PharmDProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, PennsylvaniaContent based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.Link to full program:https://bit.ly/3z8SBnC

Learn how researchers test drugs for deadly diseases like COVID-19 (without exposing participants); how Fannie Farmer transformed cooking from folk art into science; and how the Shepard scale audio illusion makes it sound like a tone is rising forever. Safety in drug trials by Ashley Hamer (Listener question from Habib) Q/A: How clinical trials test vaccines - News Story | VCU Health. (2020). Vcuhealth.org. https://www.vcuhealth.org/news-center/news-story?news=1654  Office of the Commissioner. (2019). Step 3: Clinical Research. U.S. Food and Drug Administration. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research  ‌Researchers Debate Infecting People on Purpose to Test Coronavirus Vaccines. (2020, July 1). The New York Times. https://www.nytimes.com/2020/07/01/health/coronavirus-vaccine-trials.html  Cohen, J. (2020, March 31). Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn. Science | AAAS. https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some  Coronavirus Vaccine Tracker. (2020, June 10). The New York Times. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html  How Fannie Farmer transformed cooking from folk art into science by Cameron Duke Lewis, J. J. (2017). About Fannie Farmer, Cookbook Author and Domestic Scientist. ThoughtCo. https://www.thoughtco.com/fannie-farmer-biography-3528712  Davis, S. (1984, November 25). Through the Years With The Cookbook of the Ages. Washington Post. https://www.washingtonpost.com/archive/lifestyle/food/1984/11/25/through-the-years-with-the-cookbook-of-the-ages/b3fc92c1-88f6-4fc1-be36-7a1b14450a58/  History.com Editors. (2009, November 24). Fannie Farmer opens cooking school. HISTORY. https://www.history.com/this-day-in-history/fannie-farmer-opens-cooking-school Fannie Farmer Biography. (2020). Notablebiographies.com. https://www.notablebiographies.com/Du-Fi/Farmer-Fannie.html  Engel, K. (2015, April 19). Fannie Farmer, the mother of level measurements | Amazing Women In History. https://amazingwomeninhistory.com/fannie-farmer/  Fannie Merritt Farmer | American editor | Britannica. (2019). In Encyclopædia Britannica. https://www.britannica.com/biography/Fannie-Merritt-Farmer  Moskin, J. (2018, June 13). Overlooked No More: Fannie Farmer, Modern Cookery’s Pioneer. The New York Times. https://www.nytimes.com/2018/06/13/obituaries/fannie-farmer-overlooked.html  The Shepard scale is an audio illusion that sounds like a tone is rising forever by Ashley Hamer Roger N. Shepard | American psychologist and cognitive scientist | Britannica. (2020). In Encyclopædia Britannica. https://www.britannica.com/biography/Roger-N-Shepard  ‌Shepard, R. N. (1964). Circularity in Judgments of Relative Pitch. The Journal of the Acoustical Society of America, 36(12), 2346–2353. https://doi.org/10.1121/1.1919362  What is the Shepard’s Tone? – Do you hear what I hear? (2016, July 6). Vassar.edu. https://pages.vassar.edu/seeingvoices/2016/07/06/what-is-the-shepards-tone/  ‌BBC One - Bang Goes the Theory, Series 4, Episode 6, The Shepard Tone audio illusion. (2011, April 17). BBC. https://www.bbc.co.uk/programmes/p00gfdg1  Vox. (2017). The sound illusion that makes Dunkirk so intense [YouTube Video]. In YouTube. https://www.youtube.com/watch?v=LVWTQcZbLgY  Subscribe to Curiosity Daily to learn something new every day with Cody Gough and Ashley Hamer. You can also listen to our podcast as part of your Alexa Flash Briefing; Amazon smart speakers users, click/tap “enable” here: https://www.amazon.com/Curiosity-com-Curiosity-Daily-from/dp/B07CP17DJY 

A look at PrEP, a prevention strategy for people at high risk for contracting HIV. Researchers at the University of California explain how pre-exposure prophylaxis (PrEP) works as they describe a four-year, multi-pronged study of men who have sex with men in Los Angeles and San Diego. Participants agree to take a Truvada pill daily to reduce their risk of getting infected by up to 99%. But will they follow through? Methods to increase adherence among the participants are also being tested, including daily reminders via text messages and tracking usage of the medication with special “Mems caps” for the pill bottles. [Public Affairs] [Health and Medicine] [Show ID: 25594]

A look at PrEP, a prevention strategy for people at high risk for contracting HIV. Researchers at the University of California explain how pre-exposure prophylaxis (PrEP) works as they describe a four-year, multi-pronged study of men who have sex with men in Los Angeles and San Diego. Participants agree to take a Truvada pill daily to reduce their risk of getting infected by up to 99%. But will they follow through? Methods to increase adherence among the participants are also being tested, including daily reminders via text messages and tracking usage of the medication with special “Mems caps” for the pill bottles. [Public Affairs] [Health and Medicine] [Show ID: 25594]

Dr. Diane V. Havlir explores HIV, economics and global health and Dr. Oliver Bacon explores a new HIV prevention method called PrEP, in which people who do not have HIV take a daily pill to reduce their risk of becoming infected. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 25126]

Dr. Diane V. Havlir explores HIV, economics and global health and Dr. Oliver Bacon explores a new HIV prevention method called PrEP, in which people who do not have HIV take a daily pill to reduce their risk of becoming infected. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 25126]